Compare BHAT & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHAT | TELA |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 36.7M |
| IPO Year | 2018 | 2019 |
| Metric | BHAT | TELA |
|---|---|---|
| Price | $1.43 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | ★ 70.3M | 63.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,300,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.56 |
| 52 Week Low | $0.02 | $0.67 |
| 52 Week High | $3.94 | $2.48 |
| Indicator | BHAT | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 70.57 | 48.78 |
| Support Level | $1.12 | $0.67 |
| Resistance Level | $2.05 | $0.93 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 76.98 | 70.90 |
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.